Neumora Therapeutics (NMRA) announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-898. Neumora’s M4 franchise comprises two highly potent and selective M4 muscarinic receptor positive allosteric modulators, NMRA-861 and NMRA-898, that may offer an improved therapeutic profile for schizophrenia and other neuropsychiatric disorders over standard of care. The Company previously announced the initiation of a Phase 1 SAD/MAD study with NMRA-861 in July 2025. That study and the Phase 1 SAD/MAD study with NMRA-898 announced today will each evaluate the safety, tolerability, and human pharmacokinetic data for each compound confirming the potential for once-daily dosing and central nervous system exposure of NMRA-861 and NMRA-898. Neumora plans to evaluate the strategy for its M4 franchise based on these data, potentially including advancing development of one or both programs. Neumora expects to provide a comprehensive franchise update by mid-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Reports Positive Preclinical Results for NMRA-215
- Neumora Therapeutics’ NMRA-215 shows weight loss efficacy
- Neumora Therapeuticsto hold a virtual meeting
- Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
- Neumora Therapeutics downgraded to Underweight from Neutral at JPMorgan